drugset / Trial / NCT03574571

A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

NCT03574571

Phase 3 Active not recruiting 732 enrolled Memorial Sloan Kettering Cancer Center Bayer · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetaxel alone. Earlier studies helped show that the combination is safe, but the combination has not been proven to work better than either drug alone. The goal of this study is to find out if combining docetaxel and radium-223 is better than giving either drug by itself.

Timeline

Start
2018-06-19
Primary completion
2027-04-01
Completion
2027-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Docetaxel Small molecule 60 mg/m2 Intravenous
Subject Docetaxel Small molecule 75 mg/m2 Intravenous
Subject Radium-223 dichloride Other / unclassified 0.055 mbq/kg

Indications